Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)

Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)

Abstract Statin intolerance is a clinical syndrome whereby adverse effects (AEs) associated with statin therapy [most commonly statin‐associated muscle symptoms (SAMS)] result in the discontinuation of therapy and consequently increase the risk of adverse cardiovascular outcomes. However, complete s...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron: Peter E. Penson, Eric Bruckert, David Marais, Željko Reiner, Matteo Pirro, Amirhossein Sahebkar, Gani Bajraktari, Erkin Mirrakhimov, Manfredi Rizzo, Dimitri P. Mikhailidis, Alexandros Sachinidis, Dan Gaita, Gustavs Latkovskis, Mohsen Mazidi, Peter P. Toth, Daniel Pella, Fahad Alnouri, Arman Postadzhiyan, Hung‐I Yeh, G.B. John Mancini, Stephan vonHaehling, Maciej Banach, International Lipid Expert Panel (ILEP)
Fformat: Erthygl
Iaith:English
Cyhoeddwyd: Wiley 2022-06-01
Cyfres:Journal of Cachexia, Sarcopenia and Muscle
Pynciau:
Drucebo effect
Nocebo effect
SAMS
Statin intolerance
Mynediad Ar-lein:https://doi.org/10.1002/jcsm.12960

Rhyngrwyd

https://doi.org/10.1002/jcsm.12960

Eitemau Tebyg